203 related articles for article (PubMed ID: 30606886)
1. Impact of Comorbidities and Age on Cause-Specific Mortality in Postmenopausal Patients with Breast Cancer.
Derks MGM; van de Velde CJH; Giardiello D; Seynaeve C; Putter H; Nortier JWR; Dirix LY; Bastiaannet E; Portielje JEA; Liefers GJ
Oncologist; 2019 Jul; 24(7):e467-e474. PubMed ID: 30606886
[TBL] [Abstract][Full Text] [Related]
2. Impact of age on breast cancer mortality and competing causes of death at 10 years follow-up in the adjuvant TEAM trial.
Derks MGM; Bastiaannet E; van de Water W; de Glas NA; Seynaeve C; Putter H; Nortier JWR; Rea D; Hasenburg A; Markopoulos C; Dirix LY; Portielje JEA; van de Velde CJH; Liefers GJ
Eur J Cancer; 2018 Aug; 99():1-8. PubMed ID: 29885375
[TBL] [Abstract][Full Text] [Related]
3. Impact of Older Age and Comorbidity on Locoregional and Distant Breast Cancer Recurrence: A Large Population-Based Study.
de Boer AZ; van der Hulst HC; de Glas NA; Marang-van de Mheen PJ; Siesling S; de Munck L; de Ligt KM; Portielje JEA; Bastiaannet E; Liefers GJ
Oncologist; 2020 Jan; 25(1):e24-e30. PubMed ID: 31515242
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
[TBL] [Abstract][Full Text] [Related]
5. Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.
van de Water W; Markopoulos C; van de Velde CJ; Seynaeve C; Hasenburg A; Rea D; Putter H; Nortier JW; de Craen AJ; Hille ET; Bastiaannet E; Hadji P; Westendorp RG; Liefers GJ; Jones SE
JAMA; 2012 Feb; 307(6):590-7. PubMed ID: 22318280
[TBL] [Abstract][Full Text] [Related]
6. Physical activity and survival of postmenopausal, hormone receptor-positive breast cancer patients: results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle study.
de Glas NA; Fontein DB; Bastiaannet E; Pijpe A; De Craen AJ; Liefers GJ; Nortier HJ; de Haes HJ; van de Velde CJ; van Leeuwen FE
Cancer; 2014 Sep; 120(18):2847-54. PubMed ID: 24840230
[TBL] [Abstract][Full Text] [Related]
7. The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy.
Waaijer MEC; Lemij AA; de Boer AZ; Bastiaannet E; van den Bos F; Derks MGM; Kroep JR; Liefers GJ; Portielje JEA; de Glas NA
Breast Cancer Res Treat; 2023 Oct; 201(3):471-478. PubMed ID: 37479944
[TBL] [Abstract][Full Text] [Related]
8. Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk.
Schonberg MA; Li VW; Eliassen AH; Davis RB; LaCroix AZ; McCarthy EP; Rosner BA; Chlebowski RT; Hankinson SE; Marcantonio ER; Ngo LH
Breast Cancer Res Treat; 2016 Dec; 160(3):547-562. PubMed ID: 27770283
[TBL] [Abstract][Full Text] [Related]
9. Competing Risk of Death in Elderly Patients with Newly Diagnosed Stage I Breast Cancer.
Wasif N; Neville M; Gray R; Cronin P; Pockaj BA
J Am Coll Surg; 2019 Jul; 229(1):30-36.e1. PubMed ID: 30930100
[TBL] [Abstract][Full Text] [Related]
10. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older.
Yancik R; Wesley MN; Ries LA; Havlik RJ; Edwards BK; Yates JW
JAMA; 2001 Feb; 285(7):885-92. PubMed ID: 11180731
[TBL] [Abstract][Full Text] [Related]
11. Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27.
Chapman JA; Shepherd LE; Ingle JN; Muss HB; Pritchard KI; Gelmon KA; Whelan TJ; Elliott C; Goss PE
Breast Cancer Res Treat; 2016 Apr; 156(2):343-9. PubMed ID: 27006189
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
van de Velde CJ; Rea D; Seynaeve C; Putter H; Hasenburg A; Vannetzel JM; Paridaens R; Markopoulos C; Hozumi Y; Hille ET; Kieback DG; Asmar L; Smeets J; Nortier JW; Hadji P; Bartlett JM; Jones SE
Lancet; 2011 Jan; 377(9762):321-31. PubMed ID: 21247627
[TBL] [Abstract][Full Text] [Related]
13. Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.
van Hezewijk M; Bastiaannet E; Putter H; Scholten AN; Liefers GJ; Rea D; Hasenburg A; Paridaens R; Hozumi Y; Markopoulos C; Seynaeve C; Jones SE; Marijnen CA; van de Velde CJ
Radiother Oncol; 2013 Aug; 108(2):190-6. PubMed ID: 24044798
[TBL] [Abstract][Full Text] [Related]
14. Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study.
Jordan JH; Thwin SS; Lash TL; Buist DS; Field TS; Haque R; Pawloski PA; Petersen HV; Prout MN; Quinn VP; Yood MU; Silliman RA; Geiger AM
Breast Cancer Res Treat; 2014 Jul; 146(2):401-9. PubMed ID: 24939060
[TBL] [Abstract][Full Text] [Related]
15. Potential competing risk of death in older high-risk endometrial carcinoma patients: Results from a multicentric retrospective cohort.
Gorgeu V; Borghese B; Koual M; Just PA; Lefrere Belda MA; Delanoy N; Durdux C; Chapron C; Goldwasser F; Gervais C; Blons H; Terris B; Badoual C; Taly V; Laurent-Puig P; Bats AS; Alexandre J; Beinse G
Gynecol Oncol; 2022 Aug; 166(2):269-276. PubMed ID: 35643579
[TBL] [Abstract][Full Text] [Related]
16. Competing risks of death in younger and older postmenopausal breast cancer patients.
Chapman JA; Pritchard KI; Goss PE; Ingle JN; Muss HB; Dent SF; Vandenberg TA; Findlay B; Gelmon KA; Wilson CF; Shepherd LE; Pollak MN
World J Clin Oncol; 2014 Dec; 5(5):1088-96. PubMed ID: 25493245
[TBL] [Abstract][Full Text] [Related]
17. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
18. Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: a Dutch TEAM trial analysis.
van Nes JG; Beex LV; Seynaeve C; Putter H; Sramek A; Lardenoije S; Duijm-de Carpentier M; Van Rongen I; Nortier JW; Zonderland HM; van de Velde CJ
Acta Oncol; 2015 Mar; 54(3):349-60. PubMed ID: 25383451
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
[TBL] [Abstract][Full Text] [Related]
20. Competing Causes of Death in Older Adults with Thyroid Cancer.
Papaleontiou M; Norton EC; Reyes-Gastelum D; Banerjee M; Haymart MR
Thyroid; 2021 Sep; 31(9):1359-1365. PubMed ID: 33764188
[No Abstract] [Full Text] [Related]
[Next] [New Search]
